≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Congenital hypothyroidism without goiter

Endpoint Browser PheWeb

E4_CONGENITAL_HYPOTHYROIDISM_WITHOUT_GOITER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E03.1
  • Cause of death: ICD-10 — E03.1

2 out of 7 registries used, show all original rules.

194

4. Check minimum number of events

None

194

5. Include endpoints

None

194

6. Filter based on genotype QC (FinnGen only)

183

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 183 159 24
Unadjusted period prevalence (%) 0.05 0.06 0.01
Median age at first event (years) 37.63 36.09 47.80

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
194
Matched controls
1940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E03.1
ICD-10 Finland
Congenital hypothyroidism without goitre
+∞
280.8
194
*
H03AA01
ATC
levothyroxine sodium; systemic
161.2
121.4
188
315
104
Kela drug reimbursment
Thyroid insufficiency
28.4
120.1
100
70
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
22.5
111.9
134
175
E03.89
ICD-10 Finland
Other specified hypothyroidism
15.5
46.0
44
36
T86
ICPC
Hypothyroidism/myxoedema
12.3
38.9
43
44
E03
ICD-10 Finland
Other hypothyroidism
7.4
26.5
44
74
E03.0
ICD-10 Finland
Congenital hypothyroidism with diffuse goitre
49.3
15.3
18
*
O99.2
ICD-10 Finland
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
12.9
15.3
27
24
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
14.2
14.9
25
20
A10AE04
ATC
insulin glargine; parenteral
3.6
7.6
26
79
24399
ICD-8 Finland
Cretinism of congenital origin
+∞
7.3
7
*
E03.8
ICD-10 Finland
Other specified hypothyroidism
31.3
7.2
9
*
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
4.7
7.1
17
39
A29
ICPC
General symptom/complaint other
2.8
7.0
40
165
SPAT1263
SPAT
Sampling
2.2
6.4
97
615
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
6.1
6.3
16
28
E03.3
ICD-10 Finland
Postinfectious hypothyroidism
+∞
6.3
6
*
SPAT1254
SPAT
Administration of medicine
2.6
6.2
41
182

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
1.9e+00
2.3e+00
7.1e-01
1.4e+00
1.3e+00
1.8e+00
1.0e+50
cases:98.79%
controls:92.28%
cases:97.59%
controls:79.78%
cases:57.23%
controls:39.77%
cases:9.04%
controls:2.48%
cases:70.12%
controls:39.41%
cases:96.23%
controls:80.35%
cases:100.00%
controls:94.63%
163
1518
2
127
162
1318
4
334
95
657
71
995
15
41
151
1611
115
651
49
1001
153
1313
6
321
150
1463
0
83
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
3.6e+00
3.7e+00
2.5e+00
—
2.8e+00
4.3e+00
4.9e+00
cases:76.97%
controls:8.09%
cases:79.52%
controls:8.41%
cases:21.69%
controls:2.12%
—
—
cases:27.44%
controls:2.18%
cases:87.42%
controls:8.69%
cases:94.00%
controls:10.61%
127
133
38
1512
132
139
34
1513
36
35
130
1617
—
45
36
119
1616
139
142
20
1492
141
164
9
1382
Outpatient Visit
OP [9202]
6.7e-01
9.8e-01
1.2e+00
5.8e+00
1.5e+00
1.8e+00
1.4e+00
cases:74.55%
controls:59.88%
cases:66.87%
controls:43.16%
cases:29.52%
controls:10.71%
cases:50.00%
controls:0.30%
cases:32.93%
controls:10.23%
cases:83.02%
controls:44.98%
cases:92.67%
controls:75.36%
123
985
42
660
111
713
55
939
49
177
117
1475
83
5
83
1647
54
169
110
1483
132
735
27
899
139
1165
11
381
Hypothyroidism, unspecified
E03.9 [45537945]
2.6e+00
2.7e+00
—
—
—
3.2e+00
2.6e+00
cases:15.15%
controls:1.28%
cases:10.84%
controls:0.85%
—
—
—
—
—
—
cases:16.35%
controls:0.80%
cases:24.00%
controls:2.39%
25
21
140
1624
18
14
148
1638
—
—
—
26
13
133
1621
36
37
114
1509
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
6.7e-01
1.1e+00
2.4e+00
—
2.5e+00
9.8e-01
8.1e-01
cases:16.97%
controls:9.48%
cases:16.27%
controls:6.23%
cases:6.63%
controls:0.67%
—
—
cases:7.32%
controls:0.67%
cases:16.98%
controls:7.10%
cases:34.00%
controls:18.63%
28
156
137
1489
27
103
139
1549
11
11
155
1641
—
12
11
152
1641
27
116
132
1518
51
288
99
1258
Other hypothyroidism
E03 [45581337]
2.2e+00
—
—
—
—
2.5e+00
2.3e+00
cases:6.06%
controls:0.73%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.37%
cases:10.00%
controls:1.10%
10
12
155
1633
—
—
—
—
7
6
152
1628
15
17
135
1529
Internal Medicine
11 [38004456]
9.3e-01
8.4e-01
2.0e+00
1.0e+50
1.9e+00
8.9e-01
4.2e-01
cases:35.15%
controls:17.63%
cases:18.67%
controls:9.02%
cases:8.43%
controls:1.21%
cases:19.28%
controls:0.00%
cases:7.93%
controls:1.33%
cases:18.87%
controls:8.69%
cases:28.00%
controls:20.31%
58
290
107
1355
31
149
135
1503
14
20
152
1632
32
0
134
1652
13
22
151
1630
30
142
129
1492
42
314
108
1232
Endocrinology
46 [38004485]
1.1e+00
1.5e+00
2.0e+00
1.0e+50
1.8e+00
2.0e+00
9.9e-01
cases:6.67%
controls:2.37%
cases:6.02%
controls:1.39%
cases:3.61%
controls:0.48%
cases:4.82%
controls:0.00%
cases:3.66%
controls:0.61%
cases:10.69%
controls:1.65%
cases:11.33%
controls:4.53%
11
39
154
1606
10
23
156
1629
6
8
160
1644
8
0
158
1652
6
10
158
1642
17
27
142
1607
17
70
133
1476
Emergency Room Visit
ER [9203]
5.6e-01
9.5e-01
1.9e+00
1.0e+50
1.8e+00
1.1e+00
5.9e-01
cases:41.82%
controls:29.18%
cases:22.89%
controls:10.29%
cases:9.04%
controls:1.39%
cases:18.07%
controls:0.00%
cases:7.32%
controls:1.27%
cases:29.56%
controls:12.24%
cases:46.00%
controls:32.08%
69
480
96
1165
38
170
128
1482
15
23
151
1629
30
0
136
1652
12
21
152
1631
47
200
112
1434
69
496
81
1050
Inpatient Hospital
21 [8717]
5.3e-01
9.2e-01
1.6e+00
1.0e+50
2.3e+00
1.4e+00
5.3e-01
cases:47.88%
controls:35.08%
cases:25.90%
controls:12.23%
cases:8.43%
controls:1.82%
cases:28.31%
controls:0.00%
cases:14.63%
controls:1.63%
cases:35.22%
controls:11.38%
cases:41.33%
controls:29.30%
79
577
86
1068
43
202
123
1450
14
30
152
1622
47
0
119
1652
24
27
140
1625
56
186
103
1448
62
453
88
1093
Upper gastrointestinal surgery
106 [44777669]
7.1e-01
1.7e+00
2.3e+00
—
—
1.3e+00
8.5e-01
cases:10.91%
controls:5.65%
cases:9.64%
controls:1.94%
cases:4.82%
controls:0.48%
—
—
—
—
cases:9.43%
controls:2.63%
cases:15.33%
controls:7.18%
18
93
147
1552
16
32
150
1620
8
8
158
1644
—
—
15
43
144
1591
23
111
127
1435
hydrocortisone; oral, parenteral
H02AB09 [21602737]
1.7e+00
—
—
—
—
2.4e+00
1.8e+00
cases:4.85%
controls:0.91%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.37%
cases:6.00%
controls:1.03%
8
15
157
1630
—
—
—
—
6
6
153
1628
9
16
141
1530
Psychiatry
26 [38004469]
1.5e+00
1.2e+00
9.8e-01
—
8.5e-01
1.6e+00
1.4e+00
cases:16.97%
controls:4.50%
cases:9.64%
controls:2.97%
cases:3.01%
controls:1.15%
—
—
cases:3.05%
controls:1.33%
cases:12.58%
controls:2.69%
cases:18.67%
controls:5.50%
28
74
137
1571
16
49
150
1603
5
19
161
1633
—
5
22
159
1630
20
44
139
1590
28
85
122
1461
Laboratory Visit
OMOP4822461 [32036]
7.0e-02
3.3e-01
9.6e-01
3.6e+00
1.1e+00
2.1e-01
6.6e-02
cases:20.00%
controls:18.91%
cases:24.10%
controls:18.52%
cases:16.87%
controls:7.20%
cases:9.64%
controls:0.30%
cases:16.46%
controls:6.05%
cases:25.16%
controls:21.48%
cases:40.00%
controls:38.42%
33
311
132
1334
40
306
126
1346
28
119
138
1533
16
5
150
1647
27
100
137
1552
40
351
119
1283
60
594
90
952
Outpatient Hospital
22 [8756]
3.3e-01
9.7e-01
1.5e+00
1.0e+50
2.7e+00
1.3e+00
6.2e-01
cases:32.73%
controls:25.96%
cases:17.47%
controls:7.45%
cases:4.82%
controls:1.09%
cases:13.25%
controls:0.00%
cases:9.76%
controls:0.73%
cases:24.53%
controls:7.89%
cases:34.00%
controls:21.73%
54
427
111
1218
29
123
137
1529
8
18
158
1634
22
0
144
1652
16
12
148
1640
39
129
120
1505
51
336
99
1210
Obstetrics / Gynecology
16 [38004461]
-1.2e-02
7.3e-01
1.7e+00
1.0e+50
2.5e+00
1.0e+00
3.8e-01
cases:18.79%
controls:18.97%
cases:16.27%
controls:8.60%
cases:8.43%
controls:1.69%
cases:16.87%
controls:0.00%
cases:10.37%
controls:0.97%
cases:18.24%
controls:7.59%
cases:26.67%
controls:19.92%
31
312
134
1333
27
142
139
1510
14
28
152
1624
28
0
138
1652
17
16
147
1636
29
124
130
1510
40
308
110
1238
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
5.1e-01
7.5e-01
2.1e+00
—
2.2e+00
7.8e-01
4.8e-01
cases:18.18%
controls:11.79%
cases:16.87%
controls:8.78%
cases:7.23%
controls:0.91%
—
—
cases:7.93%
controls:0.97%
cases:19.50%
controls:9.98%
cases:35.33%
controls:25.36%
30
194
135
1451
28
145
138
1507
12
15
154
1637
—
13
16
151
1636
31
163
128
1471
53
392
97
1154
Physiotherapist
Z3226 [2001311560]
1.0e+00
2.0e+00
—
—
—
2.8e+00
8.1e-01
cases:3.64%
controls:1.34%
cases:3.61%
controls:0.48%
—
—
—
—
—
—
cases:5.03%
controls:0.31%
cases:4.00%
controls:1.81%
6
22
159
1623
6
8
160
1644
—
—
—
8
5
151
1629
6
28
144
1518
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
2.3e+00
—
—
—
—
2.4e+00
1.6e+00
cases:4.24%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.31%
cases:4.00%
controls:0.84%
7
7
158
1638
—
—
—
—
5
5
154
1629
6
13
144
1533
General Practice
1 [38004446]
9.7e-01
1.3e+00
—
—
1.9e+00
8.5e-01
5.0e-01
cases:20.61%
controls:9.00%
cases:13.25%
controls:3.87%
—
—
—
—
cases:4.88%
controls:0.73%
cases:8.18%
controls:3.67%
cases:19.33%
controls:12.74%
34
148
131
1497
22
64
144
1588
—
—
8
12
156
1640
13
60
146
1574
29
197
121
1349
Case Management Agency
251B00000X [38004193]
2.5e-01
2.8e-01
5.0e-01
3.0e+00
6.6e-01
4.3e-01
2.6e-01
cases:46.67%
controls:40.61%
cases:44.58%
controls:37.89%
cases:21.69%
controls:14.41%
cases:13.25%
controls:0.79%
cases:25.00%
controls:14.65%
cases:50.31%
controls:39.60%
cases:66.00%
controls:60.03%
77
668
88
977
74
626
92
1026
36
238
130
1414
22
13
144
1639
41
242
123
1410
80
647
79
987
99
928
51
618
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.2e-01
4.8e-01
1.6e+00
—
1.6e+00
3.4e-01
1.2e-01
cases:15.15%
controls:13.62%
cases:17.47%
controls:11.62%
cases:9.04%
controls:1.88%
—
—
cases:10.37%
controls:2.18%
cases:18.24%
controls:13.65%
cases:32.00%
controls:29.50%
25
224
140
1421
29
192
137
1460
15
31
151
1621
—
17
36
147
1616
29
223
130
1411
48
456
102
1090
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.7e-01
3.3e-01
1.6e+00
—
1.6e+00
1.8e-01
-3.5e-02
cases:12.12%
controls:10.46%
cases:11.45%
controls:8.47%
cases:9.04%
controls:1.94%
—
—
cases:7.93%
controls:1.69%
cases:12.58%
controls:10.71%
cases:22.67%
controls:23.29%
20
172
145
1473
19
140
147
1512
15
32
151
1620
—
13
28
151
1624
20
175
139
1459
34
360
116
1186
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.4e-01
5.0e-01
1.5e+00
—
1.7e+00
3.1e-01
1.3e-01
cases:15.15%
controls:13.50%
cases:17.47%
controls:11.38%
cases:8.43%
controls:1.94%
—
—
cases:10.37%
controls:2.12%
cases:17.61%
controls:13.59%
cases:32.00%
controls:29.24%
25
222
140
1423
29
188
137
1464
14
32
152
1620
—
17
35
147
1617
28
222
131
1412
48
452
102
1094
CBC panel - Blood by Automated count
58410-2 [40761511]
9.6e-02
5.2e-01
1.6e+00
—
1.6e+00
3.8e-01
1.7e-01
cases:15.76%
controls:14.53%
cases:16.27%
controls:10.35%
cases:9.64%
controls:2.18%
—
—
cases:9.15%
controls:1.94%
cases:16.35%
controls:11.81%
cases:32.00%
controls:28.46%
26
239
139
1406
27
171
139
1481
16
36
150
1616
—
15
32
149
1620
26
193
133
1441
48
440
102
1106
Depressive episode, unspecified
F32.9 [45571760]
1.7e+00
—
—
—
—
—
1.5e+00
cases:6.06%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
cases:6.00%
controls:1.42%
10
20
155
1625
—
—
—
—
—
9
22
141
1524
cefalexin; oral
J01DB01 [21602870]
3.0e-01
7.1e-01
7.9e-01
—
2.3e+00
8.1e-01
4.1e-01
cases:36.36%
controls:29.67%
cases:15.06%
controls:8.05%
cases:3.01%
controls:1.39%
—
—
cases:7.93%
controls:0.85%
cases:19.50%
controls:9.73%
cases:39.33%
controls:30.01%
60
488
105
1157
25
133
141
1519
5
23
161
1629
—
13
14
151
1638
31
159
128
1475
59
464
91
1082
Orthopedic Surgery
20 [38004465]
6.1e-01
1.1e+00
2.0e+00
—
—
9.4e-01
4.8e-01
cases:16.97%
controls:10.03%
cases:11.45%
controls:4.00%
cases:4.22%
controls:0.61%
—
—
—
—
cases:9.43%
controls:3.92%
cases:21.33%
controls:14.42%
28
165
137
1480
19
66
147
1586
7
10
159
1642
—
—
15
64
144
1570
32
223
118
1323
Home Visit
OMOP4822459 [581476]
8.6e-01
1.3e+00
1.6e+00
-1.0e+50
1.7e+00
9.6e-01
5.9e-01
cases:7.27%
controls:3.22%
cases:7.23%
controls:2.12%
cases:4.22%
controls:0.85%
cases:0.00%
controls:0.42%
cases:4.88%
controls:0.91%
cases:6.29%
controls:2.51%
cases:11.33%
controls:6.60%
12
53
153
1592
12
35
154
1617
7
14
159
1638
0
7
166
1645
8
15
156
1637
10
41
149
1593
17
102
133
1444
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
8.3e-02
4.3e-01
1.4e+00
—
1.6e+00
2.6e-01
5.1e-02
cases:16.36%
controls:15.26%
cases:18.67%
controls:12.95%
cases:9.04%
controls:2.36%
—
—
cases:10.98%
controls:2.54%
cases:18.87%
controls:15.24%
cases:33.33%
controls:32.21%
27
251
138
1394
31
214
135
1438
15
39
151
1613
—
18
42
146
1610
30
249
129
1385
50
498
100
1048
Hypothyroidism caused by autoimmune thyroiditis
E03.80 [2000501406]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.67%
controls:0.52%
—
—
—
—
—
—
13
8
137
1538
Other specified hypothyroidism
E03.89 [2000501408]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.00%
controls:0.39%
—
—
—
—
—
—
9
6
141
1540
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.1e-01
7.1e-01
1.7e+00
—
1.3e+00
1.1e+00
3.4e-01
cases:16.97%
controls:10.03%
cases:11.45%
controls:5.99%
cases:5.42%
controls:1.03%
—
—
cases:4.27%
controls:1.21%
cases:15.72%
controls:6.06%
cases:21.33%
controls:16.24%
28
165
137
1480
19
99
147
1553
9
17
157
1635
—
7
20
157
1632
25
99
134
1535
32
251
118
1295
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.4e-01
8.6e-01
1.3e+00
—
1.9e+00
6.8e-01
1.6e-01
cases:15.15%
controls:12.34%
cases:18.07%
controls:8.54%
cases:6.63%
controls:1.94%
—
—
cases:10.37%
controls:1.69%
cases:16.98%
controls:9.42%
cases:29.33%
controls:26.13%
25
203
140
1442
30
141
136
1511
11
32
155
1620
—
17
28
147
1624
27
154
132
1480
44
404
106
1142
Treatment plan or consultation
WZC00 [2001310885]
7.1e-01
1.0e+00
—
—
—
1.6e+00
1.1e+00
cases:6.67%
controls:3.40%
cases:3.61%
controls:1.33%
—
—
—
—
—
—
cases:6.92%
controls:1.47%
cases:13.33%
controls:4.79%
11
56
154
1589
6
22
160
1630
—
—
—
11
24
148
1610
20
74
130
1472
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.1e-01
4.2e-01
1.3e+00
—
1.4e+00
1.6e-01
4.2e-02
cases:18.18%
controls:16.66%
cases:21.08%
controls:14.89%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.63%
cases:36.67%
controls:35.71%
30
274
135
1371
35
246
131
1406
19
57
147
1595
—
20
53
144
1599
32
288
127
1346
55
552
95
994
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.1e-01
4.2e-01
1.3e+00
—
1.4e+00
1.7e-01
4.4e-02
cases:18.18%
controls:16.60%
cases:21.08%
controls:14.89%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.56%
cases:36.67%
controls:35.64%
30
273
135
1372
35
246
131
1406
19
57
147
1595
—
20
53
144
1599
32
287
127
1347
55
551
95
995
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.0e-01
4.2e-01
1.3e+00
—
1.4e+00
1.7e-01
4.4e-02
cases:18.18%
controls:16.72%
cases:21.08%
controls:14.95%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.56%
cases:36.67%
controls:35.64%
30
275
135
1370
35
247
131
1405
19
57
147
1595
—
20
53
144
1599
32
287
127
1347
55
551
95
995
MCH [Entitic mass]
28539-5 [3035941]
1.1e-01
4.2e-01
1.3e+00
—
1.4e+00
1.7e-01
4.7e-02
cases:18.18%
controls:16.60%
cases:21.08%
controls:14.89%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.56%
cases:36.67%
controls:35.58%
30
273
135
1372
35
246
131
1406
19
57
147
1595
—
20
53
144
1599
32
287
127
1347
55
550
95
996
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.1e-01
4.2e-01
1.3e+00
—
1.4e+00
1.7e-01
4.4e-02
cases:18.18%
controls:16.60%
cases:21.08%
controls:14.89%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.56%
cases:36.67%
controls:35.64%
30
273
135
1372
35
246
131
1406
19
57
147
1595
—
20
53
144
1599
32
287
127
1347
55
551
95
995
Platelets [#/volume] in Blood
26515-7 [3007461]
1.1e-01
4.3e-01
1.3e+00
—
1.4e+00
1.7e-01
4.7e-02
cases:18.18%
controls:16.66%
cases:21.08%
controls:14.83%
cases:11.45%
controls:3.45%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.50%
cases:36.67%
controls:35.58%
30
274
135
1371
35
245
131
1407
19
57
147
1595
—
20
53
144
1599
32
286
127
1348
55
550
95
996
temazepam; oral
N05CD07 [21604642]
1.1e+00
1.6e+00
—
—
—
1.1e+00
9.0e-01
cases:8.48%
controls:2.98%
cases:6.02%
controls:1.27%
—
—
—
—
—
—
cases:4.40%
controls:1.53%
cases:6.00%
controls:2.52%
14
49
151
1596
10
21
156
1631
—
—
—
7
25
152
1609
9
39
141
1507
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.1e-01
4.2e-01
1.3e+00
—
1.4e+00
1.7e-01
4.7e-02
cases:18.18%
controls:16.60%
cases:21.08%
controls:14.95%
cases:11.45%
controls:3.51%
—
—
cases:12.20%
controls:3.21%
cases:20.13%
controls:17.56%
cases:36.67%
controls:35.58%
30
273
135
1372
35
247
131
1405
19
58
147
1594
—
20
53
144
1599
32
287
127
1347
55
550
95
996
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.0e-01
4.9e-01
1.3e+00
—
1.4e+00
1.9e-01
-2.4e-02
cases:15.76%
controls:12.16%
cases:15.66%
controls:10.23%
cases:7.83%
controls:2.24%
—
—
cases:7.93%
controls:2.12%
cases:15.09%
controls:12.85%
cases:27.33%
controls:27.81%
26
200
139
1445
26
169
140
1483
13
37
153
1615
—
13
35
151
1617
24
210
135
1424
41
430
109
1116
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
O99.2 [45534321]
—
—
—
1.0e+50
—
—
2.7e+00
—
—
—
—
—
—
cases:4.82%
controls:0.00%
—
—
—
—
cases:5.33%
controls:0.39%
—
—
—
8
0
158
1652
—
—
8
6
142
1540
ibuprofen
R02AX02 [1588667]
1.8e-01
4.7e-01
—
—
1.8e+00
8.1e-01
2.0e-01
cases:30.30%
controls:26.69%
cases:17.47%
controls:11.68%
—
—
—
—
cases:6.71%
controls:1.21%
cases:24.53%
controls:12.67%
cases:36.67%
controls:32.15%
50
439
115
1206
29
193
137
1459
—
—
11
20
153
1632
39
207
120
1427
55
497
95
1049
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
1.8e-01
4.7e-01
—
—
1.8e+00
8.1e-01
2.0e-01
cases:30.30%
controls:26.69%
cases:17.47%
controls:11.68%
—
—
—
—
cases:6.71%
controls:1.21%
cases:24.53%
controls:12.67%
cases:36.67%
controls:32.15%
50
439
115
1206
29
193
137
1459
—
—
11
20
153
1632
39
207
120
1427
55
497
95
1049
Pulmonary Disease
29 [38004472]
1.1e+00
1.5e+00
—
1.0e+50
—
1.2e+00
7.5e-01
cases:13.33%
controls:5.11%
cases:10.24%
controls:2.48%
—
—
cases:4.22%
controls:0.00%
—
—
cases:7.55%
controls:2.45%
cases:12.67%
controls:6.40%
22
84
143
1561
17
41
149
1611
—
7
0
159
1652
—
12
40
147
1594
19
99
131
1447
Ulcer of lower limb, not elsewhere classified
L97 [45591659]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.32%
—
—
—
—
—
—
6
5
144
1541
INR in Blood by Coagulation assay
34714-6 [3032080]
5.3e-01
1.2e+00
1.2e+00
1.0e+50
1.5e+00
1.2e+00
5.5e-01
cases:5.45%
controls:3.28%
cases:7.83%
controls:2.42%
cases:3.01%
controls:0.97%
cases:3.61%
controls:0.00%
cases:4.27%
controls:0.97%
cases:8.18%
controls:2.63%
cases:13.33%
controls:8.15%
9
54
156
1591
13
40
153
1612
5
16
161
1636
6
0
160
1652
7
16
157
1636
13
43
146
1591
20
126
130
1420
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.31%
—
—
—
—
—
—
—
5
5
154
1629
—
duloxetine; oral
N06AX21 [21604749]
—
—
—
—
—
2.4e+00
6.6e-01
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.31%
cases:3.33%
controls:1.75%
—
—
—
—
—
5
5
154
1629
5
27
145
1519
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
2.3e+00
—
—
—
—
—
1.6e+00
cases:4.85%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.97%
8
8
157
1637
—
—
—
—
—
7
15
143
1531
Eosinophils [#/volume] in Blood
26449-9 [3013115]
6.0e-01
3.2e-01
2.2e+00
—
-1.0e+50
4.5e-01
4.2e-01
cases:8.48%
controls:4.86%
cases:4.22%
controls:3.09%
cases:4.22%
controls:0.48%
—
—
cases:0.00%
controls:0.42%
cases:5.66%
controls:3.67%
cases:14.00%
controls:9.70%
14
80
151
1565
7
51
159
1601
7
8
159
1644
—
0
7
164
1645
9
60
150
1574
21
150
129
1396
Monocytes [#/volume] in Blood
26484-6 [3001604]
5.4e-01
3.6e-01
2.2e+00
—
-1.0e+50
6.0e-01
4.2e-01
cases:7.88%
controls:4.74%
cases:4.22%
controls:2.97%
cases:3.61%
controls:0.42%
—
—
cases:0.00%
controls:0.42%
cases:5.66%
controls:3.18%
cases:14.00%
controls:9.64%
13
78
152
1567
7
49
159
1603
6
7
160
1645
—
0
7
164
1645
9
52
150
1582
21
149
129
1397
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
4.6e-01
—
2.2e+00
—
—
5.6e-01
5.3e-01
cases:6.67%
controls:4.32%
—
—
cases:3.61%
controls:0.42%
—
—
—
—
cases:4.40%
controls:2.57%
cases:12.67%
controls:7.89%
11
71
154
1574
—
6
7
160
1645
—
—
7
42
152
1592
19
122
131
1424
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.9e-01
—
2.2e+00
—
—
3.1e-01
6.2e-01
cases:5.45%
controls:3.77%
—
—
cases:3.61%
controls:0.42%
—
—
—
—
cases:3.14%
controls:2.33%
cases:11.33%
controls:6.40%
9
62
156
1583
—
6
7
160
1645
—
—
5
38
154
1596
17
99
133
1447
Basophils [#/volume] in Blood
26444-0 [3006315]
5.4e-01
3.6e-01
2.2e+00
—
-1.0e+50
5.6e-01
4.2e-01
cases:7.88%
controls:4.74%
cases:4.22%
controls:2.97%
cases:3.61%
controls:0.42%
—
—
cases:0.00%
controls:0.42%
cases:5.66%
controls:3.30%
cases:14.00%
controls:9.70%
13
78
152
1567
7
49
159
1603
6
7
160
1645
—
0
7
164
1645
9
54
150
1580
21
150
129
1396
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
5.0e-01
3.9e-01
2.2e+00
—
-1.0e+50
5.1e-01
3.6e-01
cases:7.88%
controls:4.92%
cases:4.82%
controls:3.33%
cases:3.61%
controls:0.42%
—
—
cases:0.00%
controls:0.48%
cases:5.66%
controls:3.49%
cases:14.00%
controls:10.16%
13
81
152
1564
8
55
158
1597
6
7
160
1645
—
0
8
164
1644
9
57
150
1577
21
157
129
1389
Thyroid insufficiency
104 [2001600104]
2.1e+00
—
—
—
—
—
—
cases:4.24%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
158
1636
—
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
9.8e-01
1.2e+00
—
—
—
2.1e+00
7.3e-01
cases:6.06%
controls:2.37%
cases:3.61%
controls:1.09%
—
—
—
—
—
—
cases:3.77%
controls:0.49%
cases:7.33%
controls:3.69%
10
39
155
1606
6
18
160
1634
—
—
—
6
8
153
1626
11
57
139
1489
Monocytes/Leukocytes in Blood
26485-3 [3019069]
6.3e-01
7.9e-01
2.0e+00
—
-1.0e+50
5.0e-01
5.9e-01
cases:7.88%
controls:4.38%
cases:5.42%
controls:2.54%
cases:3.61%
controls:0.48%
—
—
cases:0.00%
controls:0.42%
cases:5.03%
controls:3.12%
cases:14.67%
controls:8.67%
13
72
152
1573
9
42
157
1610
6
8
160
1644
—
0
7
164
1645
8
51
151
1583
22
134
128
1412
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
6.1e-01
7.4e-01
2.0e+00
—
-1.0e+50
5.0e-01
5.9e-01
cases:7.88%
controls:4.44%
cases:5.42%
controls:2.66%
cases:3.61%
controls:0.48%
—
—
cases:0.00%
controls:0.42%
cases:5.03%
controls:3.12%
cases:14.67%
controls:8.73%
13
73
152
1572
9
44
157
1608
6
8
160
1644
—
0
7
164
1645
8
51
151
1583
22
135
128
1411
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
5.5e-01
5.7e-01
2.0e+00
—
-1.0e+50
4.8e-01
6.1e-01
cases:7.27%
controls:4.32%
cases:4.82%
controls:2.78%
cases:3.61%
controls:0.48%
—
—
cases:0.00%
controls:0.36%
cases:5.03%
controls:3.18%
cases:14.67%
controls:8.54%
12
71
153
1574
8
46
158
1606
6
8
160
1644
—
0
6
164
1646
8
52
151
1582
22
132
128
1414
Basophils/Leukocytes in Blood
30180-4 [3022096]
6.4e-01
7.4e-01
2.0e+00
—
-1.0e+50
5.0e-01
5.9e-01
cases:7.88%
controls:4.32%
cases:5.42%
controls:2.66%
cases:3.61%
controls:0.48%
—
—
cases:0.00%
controls:0.42%
cases:5.03%
controls:3.12%
cases:14.67%
controls:8.67%
13
71
152
1574
9
44
157
1608
6
8
160
1644
—
0
7
164
1645
8
51
151
1583
22
134
128
1412
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
5.7e-01
6.5e-01
2.0e+00
—
-1.0e+50
4.4e-01
5.2e-01
cases:7.88%
controls:4.62%
cases:5.42%
controls:2.91%
cases:3.61%
controls:0.48%
—
—
cases:0.00%
controls:0.48%
cases:5.03%
controls:3.30%
cases:14.67%
controls:9.25%
13
76
152
1569
9
48
157
1604
6
8
160
1644
—
0
8
164
1644
8
54
151
1580
22
143
128
1403
Heart failure, unspecified
I50.9 [45576879]
2.0e+00
—
—
—
—
—
1.4e+00
cases:4.85%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:1.03%
8
11
157
1634
—
—
—
—
—
6
16
144
1530
Pediatric Medicine
37 [38004477]
2.1e-01
4.7e-01
—
—
9.6e-01
1.0e+00
9.6e-01
cases:7.88%
controls:6.50%
cases:7.83%
controls:5.02%
—
—
—
—
cases:5.49%
controls:2.18%
cases:15.72%
controls:6.24%
cases:16.67%
controls:7.12%
13
107
152
1538
13
83
153
1569
—
—
9
36
155
1616
25
102
134
1532
25
110
125
1436
Physiotherapy
R4110 [2001310233]
5.3e-01
1.1e+00
—
—
—
1.9e+00
5.9e-01
cases:4.85%
controls:2.92%
cases:3.61%
controls:1.27%
—
—
—
—
—
—
cases:4.40%
controls:0.67%
cases:6.00%
controls:3.43%
8
48
157
1597
6
21
160
1631
—
—
—
7
11
152
1623
9
53
141
1493
General Surgery
2 [38004447]
8.1e-01
8.8e-01
1.7e+00
1.0e+50
—
1.1e+00
5.0e-01
cases:32.73%
controls:17.75%
cases:10.24%
controls:4.54%
cases:3.01%
controls:0.54%
cases:4.82%
controls:0.00%
—
—
cases:15.09%
controls:5.69%
cases:22.67%
controls:15.14%
54
292
111
1353
17
75
149
1577
5
9
161
1643
8
0
158
1652
—
24
93
135
1541
34
234
116
1312
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.9e-02
5.2e-01
1.7e+00
1.0e+50
1.0e+00
2.5e-01
3.3e-01
cases:9.09%
controls:8.69%
cases:9.04%
controls:5.57%
cases:4.82%
controls:0.91%
cases:3.61%
controls:0.00%
cases:3.66%
controls:1.33%
cases:7.55%
controls:6.00%
cases:21.33%
controls:16.36%
15
143
150
1502
15
92
151
1560
8
15
158
1637
6
0
160
1652
6
22
158
1630
12
98
147
1536
32
253
118
1293
Shortness of breath/dyspnoea
R02 [2002000883]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.33%
controls:1.42%
—
—
—
—
—
—
11
22
139
1524
Urgent procedure
ZXD05 [2001311386]
-2.7e-01
—
—
—
—
1.7e+00
2.5e-01
cases:3.03%
controls:3.95%
—
—
—
—
—
—
—
—
cases:6.29%
controls:1.22%
cases:5.33%
controls:4.20%
5
65
160
1580
—
—
—
—
10
20
149
1614
8
65
142
1481
Outcome of delivery
Z37 [45581024]
-3.5e-01
-1.0e+50
-1.0e+50
—
—
1.7e+00
3.3e-01
cases:5.45%
controls:7.60%
cases:0.00%
controls:2.66%
cases:0.00%
controls:0.42%
—
—
—
—
cases:9.43%
controls:1.90%
cases:9.33%
controls:6.92%
9
125
156
1520
0
44
166
1608
0
7
166
1645
—
—
15
31
144
1603
14
107
136
1439
clopidogrel; oral
B01AC04 [21600989]
—
1.5e+00
—
—
—
1.7e+00
9.8e-01
—
—
cases:3.61%
controls:0.85%
—
—
—
—
—
—
cases:5.03%
controls:0.98%
cases:4.67%
controls:1.81%
—
6
14
160
1638
—
—
—
8
16
151
1618
7
28
143
1518
Chest pain, unspecified
R07.4 [45558450]
2.1e-01
—
—
1.0e+50
—
1.7e+00
1.0e+00
cases:3.64%
controls:2.98%
—
—
—
—
cases:3.01%
controls:0.00%
—
—
cases:5.03%
controls:0.98%
cases:8.67%
controls:3.23%
6
49
159
1596
—
—
5
0
161
1652
—
8
16
151
1618
13
50
137
1496
Antenatal screening for malformation
717800004 [36713462]
—
1.7e+00
—
—
—
—
4.1e-01
—
—
cases:8.43%
controls:1.69%
—
—
—
—
—
—
—
—
cases:6.67%
controls:4.53%
—
14
28
152
1624
—
—
—
—
10
70
140
1476
Supplier / Service Provider
OMOP5117446 [33004]
-1.7e+00
5.5e-02
—
—
—
—
3.3e+00
cases:5.45%
controls:23.53%
cases:6.63%
controls:6.30%
—
—
—
—
—
—
—
—
cases:10.00%
controls:0.39%
9
387
156
1258
11
104
155
1548
—
—
—
—
15
6
135
1540
Nonallergic asthma
J45.1 [45557625]
1.6e+00
—
—
1.0e+50
—
—
—
cases:4.85%
controls:0.97%
—
—
—
—
cases:3.01%
controls:0.00%
—
—
—
—
—
—
8
16
157
1629
—
—
5
0
161
1652
—
—
—
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
—
1.6e+00
—
—
—
—
5.9e-01
—
—
cases:4.82%
controls:0.97%
—
—
—
—
—
—
—
—
cases:5.33%
controls:3.04%
—
8
16
158
1636
—
—
—
—
8
47
142
1499
Spontaneous vertex delivery
O80.0 [45577661]
—
-1.0e+50
—
—
—
1.6e+00
3.9e-01
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
cases:6.29%
controls:1.29%
cases:6.00%
controls:4.14%
—
0
24
166
1628
—
—
—
10
21
149
1613
9
64
141
1482
enoxaparin; parenteral
B01AB05 [21600976]
2.7e-01
—
—
—
—
1.6e+00
3.9e-01
cases:4.24%
controls:3.28%
—
—
—
—
—
—
—
—
cases:5.66%
controls:1.22%
cases:6.00%
controls:4.14%
7
54
158
1591
—
—
—
—
9
20
150
1614
9
64
141
1482
Cardiology
6 [38004451]
8.3e-01
1.1e+00
—
1.0e+50
—
1.6e+00
8.0e-01
cases:12.12%
controls:5.65%
cases:7.23%
controls:2.42%
—
—
cases:3.61%
controls:0.00%
—
—
cases:10.06%
controls:2.26%
cases:14.67%
controls:7.18%
20
93
145
1552
12
40
154
1612
—
6
0
160
1652
—
16
37
143
1597
22
111
128
1435
Essential (primary) hypertension
I10 [45591453]
1.7e-01
5.3e-01
9.3e-01
—
1.5e+00
8.4e-01
3.9e-01
cases:13.33%
controls:11.49%
cases:9.64%
controls:5.93%
cases:3.01%
controls:1.21%
—
—
cases:6.10%
controls:1.39%
cases:13.84%
controls:6.49%
cases:22.00%
controls:16.04%
22
189
143
1456
16
98
150
1554
5
20
161
1632
—
10
23
154
1629
22
106
137
1528
33
248
117
1298
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
—
—
—
—
—
2.0e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.43%
cases:6.00%
controls:1.42%
—
—
—
—
—
5
7
154
1627
9
22
141
1524
quetiapine; oral
N05AH04 [21604544]
1.1e+00
—
-1.0e+50
—
—
—
1.4e+00
cases:6.67%
controls:2.37%
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:8.00%
controls:2.01%
11
39
154
1606
—
0
14
166
1638
—
—
—
12
31
138
1515
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.1e+00
1.3e+00
—
—
—
1.7e+00
1.4e+00
cases:5.45%
controls:1.82%
cases:3.01%
controls:0.85%
—
—
—
—
—
—
cases:3.77%
controls:0.73%
cases:8.00%
controls:2.13%
9
30
156
1615
5
14
161
1638
—
—
—
6
12
153
1622
12
33
138
1513
Thorax X-ray examination
GD1AA [2001303617]
4.0e-01
1.3e+00
—
1.0e+50
—
9.1e-01
8.5e-01
cases:6.67%
controls:4.56%
cases:6.63%
controls:1.82%
—
—
cases:5.42%
controls:0.00%
—
—
cases:5.03%
controls:2.08%
cases:12.67%
controls:5.82%
11
75
154
1570
11
30
155
1622
—
9
0
157
1652
—
8
34
151
1600
19
90
131
1456
Telephone prescription or other care instructions
WZB00 [2001310884]
8.8e-01
—
—
—
—
—
1.3e+00
cases:7.27%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:12.00%
controls:3.69%
12
52
153
1593
—
—
—
—
—
18
57
132
1489
furosemide; oral, parenteral
C03CA01 [21601518]
1.2e+00
1.1e+00
1.5e+00
—
1.5e+00
8.3e-01
7.1e-01
cases:12.12%
controls:4.01%
cases:6.63%
controls:2.36%
cases:3.01%
controls:0.67%
—
—
cases:3.05%
controls:0.73%
cases:7.55%
controls:3.43%
cases:10.67%
controls:5.56%
20
66
145
1579
11
39
155
1613
5
11
161
1641
—
5
12
159
1640
12
56
147
1578
16
86
134
1460
Other and unspecified abdominal pain
R10.4 [45568113]
1.1e+00
—
—
—
—
6.7e-01
5.6e-01
cases:10.91%
controls:3.77%
—
—
—
—
—
—
—
—
cases:3.77%
controls:1.96%
cases:9.33%
controls:5.56%
18
62
147
1583
—
—
—
—
6
32
153
1602
14
86
136
1460
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.1e+00
-1.0e+50
—
—
—
—
6.2e-01
cases:8.48%
controls:2.92%
cases:0.00%
controls:1.09%
—
—
—
—
—
—
—
—
cases:6.67%
controls:3.69%
14
48
151
1597
0
18
166
1634
—
—
—
—
10
57
140
1489
prednisolone
A07EA01 [21600653]
4.8e-01
6.3e-01
—
—
2.0e+00
1.0e+00
1.1e+00
cases:10.91%
controls:7.05%
cases:5.42%
controls:2.97%
—
—
—
—
cases:3.05%
controls:0.42%
cases:8.18%
controls:3.12%
cases:21.33%
controls:8.41%
18
116
147
1529
9
49
157
1603
—
—
5
7
159
1645
13
51
146
1583
32
130
118
1416
Neurology
13 [38004458]
3.4e-01
8.0e-01
1.4e+00
—
—
1.1e+00
4.0e-01
cases:12.73%
controls:9.36%
cases:7.23%
controls:3.39%
cases:3.01%
controls:0.73%
—
—
—
—
cases:8.81%
controls:3.18%
cases:13.33%
controls:9.31%
21
154
144
1491
12
56
154
1596
5
12
161
1640
—
—
14
52
145
1582
20
144
130
1402
mirtazapine; oral
N06AX11 [21604740]
1.1e+00
9.2e-01
—
—
1.6e+00
6.0e-01
6.5e-01
cases:12.12%
controls:4.56%
cases:6.02%
controls:2.48%
—
—
—
—
cases:3.66%
controls:0.79%
cases:5.03%
controls:2.82%
cases:13.33%
controls:7.44%
20
75
145
1570
10
41
156
1611
—
—
6
13
158
1639
8
46
151
1588
20
115
130
1431
prednisolone; oral, parenteral
H02AB06 [21602734]
4.8e-01
6.5e-01
—
—
2.2e+00
1.0e+00
1.0e+00
cases:10.91%
controls:7.05%
cases:5.42%
controls:2.91%
—
—
—
—
cases:3.05%
controls:0.36%
cases:8.18%
controls:3.12%
cases:20.67%
controls:8.41%
18
116
147
1529
9
48
157
1604
—
—
5
6
159
1646
13
51
146
1583
31
130
119
1416
doxycycline; oral, parenteral
J01AA02 [21602800]
4.1e-01
5.5e-01
-1.0e+50
—
—
9.6e-01
3.5e-01
cases:24.85%
controls:18.05%
cases:7.83%
controls:4.66%
cases:0.00%
controls:0.73%
—
—
—
—
cases:11.95%
controls:4.96%
cases:21.33%
controls:16.11%
41
297
124
1348
13
77
153
1575
0
12
166
1640
—
—
19
81
140
1553
32
249
118
1297
hydrocortisone
S02BA01 [21605166]
4.6e-01
—
-1.0e+50
—
—
—
9.1e-01
cases:8.48%
controls:5.53%
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:14.00%
controls:6.14%
14
91
151
1554
—
0
5
166
1647
—
—
—
21
95
129
1451
Acute upper respiratory infection, unspecified
J06.9 [45562437]
7.9e-02
—
—
—
-1.0e+50
—
8.7e-01
cases:4.85%
controls:4.50%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
cases:17.33%
controls:8.09%
8
74
157
1571
—
—
—
0
5
164
1647
—
26
125
124
1421
hydrocortisone aceponate
D07AC16 [21602135]
4.0e-01
—
-1.0e+50
—
—
3.1e-01
8.5e-01
cases:9.09%
controls:6.26%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.18%
15
103
150
1542
—
0
6
166
1646
—
—
5
38
154
1596
23
111
127
1435
hydrocortisone butyrate
D07AB02 [21602106]
4.0e-01
—
-1.0e+50
—
—
3.1e-01
8.5e-01
cases:9.09%
controls:6.26%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.18%
15
103
150
1542
—
0
6
166
1646
—
—
5
38
154
1596
23
111
127
1435
hydrocortisone
D07AA02 [21602102]
4.0e-01
—
-1.0e+50
—
—
3.1e-01
8.5e-01
cases:9.09%
controls:6.26%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.18%
15
103
150
1542
—
0
6
166
1646
—
—
5
38
154
1596
23
111
127
1435
hydrocortisone buteprate
D07AB11 [21602115]
4.0e-01
—
-1.0e+50
—
—
3.1e-01
8.5e-01
cases:9.09%
controls:6.26%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.18%
15
103
150
1542
—
0
6
166
1646
—
—
5
38
154
1596
23
111
127
1435
hydrocortisone
A07EA02 [21600654]
4.6e-01
—
-1.0e+50
—
—
3.1e-01
8.3e-01
cases:9.70%
controls:6.32%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.31%
16
104
149
1541
—
0
6
166
1646
—
—
5
38
154
1596
23
113
127
1433
hydrocortisone
C05AA01 [21601608]
4.6e-01
—
-1.0e+50
—
—
3.1e-01
8.3e-01
cases:9.70%
controls:6.32%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.14%
controls:2.33%
cases:15.33%
controls:7.31%
16
104
149
1541
—
0
6
166
1646
—
—
5
38
154
1596
23
113
127
1433
Office Visit
OMOP4822458 [581477]
8.2e-01
9.6e-01
—
1.0e+50
—
6.3e-01
6.9e-01
cases:15.76%
controls:7.60%
cases:9.64%
controls:3.93%
—
—
cases:3.01%
controls:0.00%
—
—
cases:8.18%
controls:4.53%
cases:18.67%
controls:10.35%
26
125
139
1520
16
65
150
1587
—
5
0
161
1652
—
13
74
146
1560
28
160
122
1386
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.0e-01
4.4e-01
6.0e-01
—
1.2e+00
7.4e-01
4.8e-01
cases:32.12%
controls:22.31%
cases:18.67%
controls:12.83%
cases:4.22%
controls:2.36%
—
—
cases:6.71%
controls:2.18%
cases:24.53%
controls:13.40%
cases:44.00%
controls:32.79%
53
367
112
1278
31
212
135
1440
7
39
159
1613
—
11
36
153
1616
39
219
120
1415
66
507
84
1039
More than one and less than three hours
ZXE10 [2001311401]
2.2e-01
8.3e-01
—
1.0e+50
—
1.5e+00
1.0e+00
cases:5.45%
controls:4.44%
cases:3.01%
controls:1.33%
—
—
cases:3.01%
controls:0.00%
—
—
cases:4.40%
controls:0.98%
cases:8.00%
controls:2.98%
9
73
156
1572
5
22
161
1630
—
5
0
161
1652
—
7
16
152
1618
12
46
138
1500
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
6.1e-01
—
-1.0e+50
—
-1.0e+50
—
-3.0e-01
cases:3.64%
controls:2.01%
—
—
cases:0.00%
controls:0.30%
—
—
cases:0.00%
controls:0.42%
—
—
cases:4.00%
controls:5.30%
6
33
159
1612
—
0
5
166
1647
—
0
7
164
1645
—
6
82
144
1464
Extensive health check-up of expecting family
SPAT1197 [2001700298]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
0
11
159
1623
—
Gastroenterology
10 [38004455]
7.9e-01
—
-1.0e+50
—
—
—
7.2e-01
cases:5.45%
controls:2.55%
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:8.00%
controls:4.08%
9
42
156
1603
—
0
5
166
1647
—
—
—
12
63
138
1483
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:3.33%
controls:1.16%
—
—
—
—
—
0
5
159
1629
5
18
145
1528
budesonide; nasal
R01AD05 [21605047]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
8
165
1637
—
—
—
—
—
0
8
150
1538
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
165
1637
—
—
—
—
—
—
Maternal care for poor fetal growth
O36.5 [45592238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
165
1637
—
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
9
166
1643
—
—
—
0
9
159
1625
—
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
5
166
1647
—
—
—
0
6
159
1628
—
hyaluronic acid
S01KA01 [21605114]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
5
165
1640
—
—
—
—
—
0
8
150
1538
Counselling, unspecified
Z71.9 [45561648]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.71%
—
—
—
—
—
—
5
11
145
1535
Irritable bowel syndrome with diarrhoea
K58.0 [45596336]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
10
150
1536
azathioprine; oral, parenteral
L04AX01 [21603927]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.45%
—
—
—
—
—
0
6
159
1628
0
7
150
1539
Insulin glargine 300 U / ml
177 [2001600176]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
150
1538
Laceration/cut
S18 [2002000983]
3.4e-01
9.8e-01
—
—
—
—
6.0e-01
cases:5.45%
controls:3.95%
cases:3.61%
controls:1.39%
—
—
—
—
—
—
—
—
cases:12.00%
controls:6.99%
9
65
156
1580
6
23
160
1629
—
—
—
—
18
108
132
1438
Periodontal treatment by dental hygienist
SDE02 [2001310350]
8.3e-02
—
—
—
—
—
8.0e-01
cases:3.03%
controls:2.80%
—
—
—
—
—
—
—
—
—
—
cases:7.33%
controls:3.43%
5
46
160
1599
—
—
—
—
—
11
53
139
1493
insulin aspart; parenteral
A10AD05 [21600733]
5.7e-01
4.8e-01
—
—
—
2.0e-01
-3.2e-02
cases:4.85%
controls:2.80%
cases:4.22%
controls:2.66%
—
—
—
—
—
—
cases:3.77%
controls:3.12%
cases:5.33%
controls:5.50%
8
46
157
1599
7
44
159
1608
—
—
—
6
51
153
1583
8
85
142
1461
Upper respiratory infection acute
R74 [2002000942]
1.6e-01
—
—
—
—
1.4e+00
4.7e-01
cases:3.64%
controls:3.10%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.92%
cases:7.33%
controls:4.72%
6
51
159
1594
—
—
—
—
6
15
153
1619
11
73
139
1473
General anesthesia, balanced
WX408 [2001310808]
2.5e-01
—
—
—
—
1.7e+00
4.7e-01
cases:3.64%
controls:2.86%
—
—
—
—
—
—
—
—
cases:3.77%
controls:0.73%
cases:4.67%
controls:2.98%
6
47
159
1598
—
—
—
—
6
12
153
1622
7
46
143
1500
dutasteride; oral
G04CB02 [21602676]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
5
165
1640
—
—
—
—
—
0
5
150
1541
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
-4.4e-02
-1.0e+50
—
—
—
—
—
cases:3.03%
controls:3.16%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
5
52
160
1593
0
6
166
1646
—
—
—
—
—
Weakness/tiredness general
A04 [2002000145]
1.1e+00
—
—
—
—
-1.0e+50
4.0e-01
cases:4.24%
controls:1.40%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:3.33%
controls:2.26%
7
23
158
1622
—
—
—
—
0
6
159
1628
5
35
145
1511
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
6
159
1628
—
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1647
—
—
—
—
—
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
0
15
150
1531
Labour and delivery complicated by fetal heart rate anomaly
O68.0 [45548818]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
4.1e-01
6.1e-01
-1.0e+50
—
—
6.8e-01
5.9e-01
cases:9.09%
controls:6.20%
cases:3.61%
controls:2.00%
cases:0.00%
controls:0.42%
—
—
—
—
cases:5.66%
controls:2.94%
cases:13.33%
controls:7.83%
15
102
150
1543
6
33
160
1619
0
7
166
1645
—
—
9
48
150
1586
20
121
130
1425
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.4e-01
1.2e-01
—
—
—
3.8e-01
1.2e-01
cases:8.48%
controls:7.48%
cases:5.42%
controls:4.84%
—
—
—
—
—
—
cases:6.92%
controls:4.83%
cases:17.33%
controls:15.65%
14
123
151
1522
9
80
157
1572
—
—
—
11
79
148
1555
26
242
124
1304
Postmenopausal atrophic vaginitis
N95.2 [45582430]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
165
1637
—
—
—
—
—
—
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
C50.21 [2000500994]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.65%
0
9
165
1636
0
5
166
1647
—
—
—
0
8
159
1626
0
10
150
1536
Presence of external hearing-aid
Z97.4 [45542504]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
salbutamol; inhalant
R03AC02 [21603256]
5.9e-01
3.3e-01
—
—
—
6.4e-01
5.6e-01
cases:18.18%
controls:11.00%
cases:7.83%
controls:5.75%
—
—
—
—
—
—
cases:9.43%
controls:5.20%
cases:22.00%
controls:13.84%
30
181
135
1464
13
95
153
1557
—
—
—
15
85
144
1549
33
214
117
1332
Pain, unspecified
R52.9 [45544151]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1647
—
—
—
—
—
Result test/procedure
-60 [2002000131]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
165
1637
—
—
—
—
—
—
Exposure to other and unspecified inanimate mechanical forces
W49 [45756300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Pressure/tightness of heart
K02 [2002000545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Periodontal treatment
SDA03 [2001310328]
5.7e-01
—
—
—
—
—
3.9e-01
cases:4.85%
controls:2.80%
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:4.59%
8
46
157
1599
—
—
—
—
—
10
71
140
1475
oxybutynin; oral, transdermal
G04BD04 [21602637]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1646
—
—
—
—
—
Emergency Medicine
93 [38004510]
6.1e-01
6.0e-01
—
—
—
6.3e-01
2.3e-01
cases:9.70%
controls:5.53%
cases:6.02%
controls:3.39%
—
—
—
—
—
—
cases:7.55%
controls:4.16%
cases:16.67%
controls:13.71%
16
91
149
1554
10
56
156
1596
—
—
—
12
68
147
1566
25
212
125
1334
Varicose veins of lower extremities
I83 [45567245]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Tear of meniscus, current
S83.2 [45555441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Allergic rhinitis, unspecified
J30.4 [45548110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Viral disease other/NOS
A77 [2002000211]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
Enthesopathy, unspecified
M77.9 [45591933]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
7
165
1638
—
—
—
—
—
0
7
150
1539
ofloxacin; oral, parenteral
J01MA01 [21603008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
150
1538
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
150
1537
Rheumatology
66 [38004491]
1.1e+00
—
—
—
-1.0e+50
7.8e-01
3.6e-01
cases:6.67%
controls:2.37%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:3.14%
controls:1.47%
cases:4.67%
controls:3.30%
11
39
154
1606
—
—
—
0
6
164
1646
5
24
154
1610
7
51
143
1495
acetylcysteine; inhalant, oral
R05CB01 [21603380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
fluoxetine; oral
N06AB03 [21604711]
7.4e-01
—
—
—
—
—
—
cases:3.64%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
6
29
159
1616
—
—
—
—
—
—
Amniocentesis
MAA00 [2001306845]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Sinus symptom/complaint
R09 [2002000890]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1629
—
Counselling and guidance related to occupational health
SPAT1311 [2001700412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Diabetes, non-insulin-treated
215 [2001600211]
-1.0e+50
—
—
—
—
—
3.2e-01
cases:0.00%
controls:1.34%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:3.43%
0
22
165
1623
—
—
—
—
—
7
53
143
1493
oxcarbazepine; oral
N03AF02 [21604418]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.91%
—
0
8
166
1644
—
—
—
0
7
159
1627
0
14
150
1532
Discission of sheath of tendon of wrist or hand
NDM40 [2001307726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
insulin (human); parenteral
A10AD01 [21600729]
-3.6e-01
-2.2e-01
—
—
—
-2.5e-01
-7.6e-01
cases:6.06%
controls:8.45%
cases:5.42%
controls:6.66%
—
—
—
—
—
—
cases:5.03%
controls:6.36%
cases:3.33%
controls:6.86%
10
139
155
1506
9
110
157
1542
—
—
—
8
104
151
1530
5
106
145
1440
Other primary gonarthrosis
M17.1 [45596493]
1.1e+00
1.6e+00
—
—
—
—
3.4e-01
cases:7.27%
controls:2.61%
cases:3.61%
controls:0.79%
—
—
—
—
—
—
—
—
cases:3.33%
controls:2.39%
12
43
153
1602
6
13
160
1639
—
—
—
—
5
37
145
1509
Blasts/Leukocytes in Blood
26446-5 [3025159]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
0
8
165
1637
—
—
—
—
0
5
159
1629
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
5.0e-01
—
—
—
—
2.1e-01
-1.8e-02
cases:6.67%
controls:4.13%
—
—
—
—
—
—
—
—
cases:4.40%
controls:3.61%
cases:11.33%
controls:11.51%
11
68
154
1577
—
—
—
—
7
59
152
1575
17
178
133
1368
Dysphagia
R13 [45573013]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1629
—
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
150
1537
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:2.01%
—
—
—
—
—
—
5
31
145
1515
fusidic acid
D09AA02 [21602265]
—
—
—
—
—
—
-1.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:3.69%
—
—
—
—
—
—
5
57
145
1489
Hystero-salpingography with ultrasound
LC2HE [2001306546]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Lyme disease
A69.2 [45595594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
Anogenital (venereal) warts
A63.0 [45585929]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
5
165
1640
—
—
—
—
—
0
5
150
1541
chlorhexidine, combinations
D08AC52 [21602208]
8.2e-01
—
—
—
—
—
1.4e+00
cases:3.64%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.81%
6
27
159
1618
—
—
—
—
—
10
28
140
1518
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
165
1638
—
—
—
—
—
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
1.5e-01
1.7e-01
-1.0e+50
—
—
-3.3e-01
1.9e-03
cases:13.94%
controls:12.22%
cases:10.84%
controls:9.32%
cases:0.00%
controls:0.73%
—
—
—
—
cases:8.18%
controls:11.02%
cases:27.33%
controls:27.30%
23
201
142
1444
18
154
148
1498
0
12
166
1640
—
—
13
180
146
1454
41
422
109
1124
insulin lispro; parenteral
A10AC04 [21600726]
5.0e-01
1.0e-01
—
—
—
2.1e-01
-2.3e-01
cases:4.24%
controls:2.61%
cases:3.01%
controls:2.72%
—
—
—
—
—
—
cases:4.40%
controls:3.61%
cases:4.67%
controls:5.82%
7
43
158
1602
5
45
161
1607
—
—
—
7
59
152
1575
7
90
143
1456
Supervision of other high-risk pregnancies
Z35.8 [45552076]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:1.16%
—
—
—
—
—
—
5
18
145
1528
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
4.7e-01
—
—
—
—
—
9.8e-01
cases:4.85%
controls:3.10%
—
—
—
—
—
—
—
—
—
—
cases:8.00%
controls:3.17%
8
51
157
1594
—
—
—
—
—
12
49
138
1497
Three-surface restoration
SFA30 [2001310360]
-2.5e-01
9.0e-01
—
—
—
—
8.0e-01
cases:3.64%
controls:4.62%
cases:4.22%
controls:1.76%
—
—
—
—
—
—
—
—
cases:13.33%
controls:6.47%
6
76
159
1569
7
29
159
1623
—
—
—
—
20
100
130
1446
Diabetic maculopathy
H36.01 [2000502321]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1629
—
olopatadine
R01AC08 [21605040]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
150
1537
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
10
150
1536
Sensorineural hearing loss, bilateral
H90.3 [45576850]
6.3e-01
—
—
—
—
—
4.9e-01
cases:3.03%
controls:1.64%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:2.91%
5
27
160
1618
—
—
—
—
—
7
45
143
1501
Ophthalmology
18 [38004463]
6.6e-01
1.7e-01
—
—
—
4.9e-01
5.0e-01
cases:20.61%
controls:11.79%
cases:7.23%
controls:6.17%
—
—
—
—
—
—
cases:10.06%
controls:6.43%
cases:22.67%
controls:15.07%
34
194
131
1451
12
102
154
1550
—
—
—
16
105
143
1529
34
233
116
1313
metronidazole; vaginal
G01AF01 [21602392]
—
-1.0e+50
—
—
—
-1.0e+50
8.9e-01
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:4.00%
controls:1.68%
—
0
10
166
1642
—
—
—
0
11
159
1623
6
26
144
1520
Wrist X-ray examination
ND1AA [2001307576]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.0e-01
4.5e-01
1.2e+00
—
—
2.9e-01
3.8e-01
cases:8.48%
controls:5.84%
cases:6.02%
controls:3.93%
cases:3.01%
controls:0.91%
—
—
—
—
cases:6.29%
controls:4.77%
cases:15.33%
controls:11.06%
14
96
151
1549
10
65
156
1587
5
15
161
1637
—
—
10
78
149
1556
23
171
127
1375
Gynaecological examination
SPAT1192 [2001700293]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1645
—
—
—
—
—
nepafenac
S01BC10 [21603648]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1647
—
—
—
—
—
Breast Pathology biopsy report
66110-8 [40768793]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Hearing loss, unspecified
H91.9 [45547996]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
5
165
1640
—
—
—
—
—
0
7
150
1539
alendronic acid; oral
M05BA04 [21604152]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
0
6
164
1646
—
—
pivmecillinam; oral
J01CA08 [21602827]
4.6e-01
3.3e-01
-1.0e+50
—
-1.0e+50
2.8e-01
2.9e-02
cases:13.94%
controls:9.24%
cases:4.82%
controls:3.51%
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.36%
cases:4.40%
controls:3.37%
cases:12.67%
controls:12.35%
23
152
142
1493
8
58
158
1594
0
6
166
1646
—
0
6
164
1646
7
55
152
1579
19
191
131
1355
Oncology Clinic/Center
261QX0200X [38004268]
6.1e-02
—
—
—
—
—
—
cases:3.03%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
—
—
5
47
160
1598
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
3.9e-02
—
—
—
—
8.7e-01
2.7e-01
cases:3.03%
controls:2.92%
—
—
—
—
—
—
—
—
cases:4.40%
controls:1.90%
cases:6.67%
controls:5.17%
5
48
160
1597
—
—
—
—
7
31
152
1603
10
80
140
1466
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
165
1640
—
—
—
—
—
0
6
150
1540
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Female infertility, unspecified
N97.9 [45582432]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.84%
—
—
—
—
—
0
5
159
1629
0
13
150
1533
One-surface restoration
SFA10 [2001310358]
6.6e-01
6.6e-01
—
—
—
2.6e-01
3.9e-01
cases:12.73%
controls:6.99%
cases:4.82%
controls:2.54%
—
—
—
—
—
—
cases:5.03%
controls:3.92%
cases:17.33%
controls:12.48%
21
115
144
1530
8
42
158
1610
—
—
—
8
64
151
1570
26
193
124
1353
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.91%
—
—
—
—
—
0
5
159
1629
0
14
150
1532
Skin colour change
S08 [2002000973]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Laboratory test
15220000 [4034850]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.00%
controls:3.30%
—
—
—
—
—
—
9
51
141
1495
Prolonged second stage (of labour)
O63.1 [45601878]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
150
1538
bisoprolol; oral
C07AB07 [21601689]
4.1e-02
2.3e-01
3.2e-01
—
6.8e-01
1.2e-01
-1.1e-01
cases:10.91%
controls:10.52%
cases:12.05%
controls:9.81%
cases:4.22%
controls:3.09%
—
—
cases:5.49%
controls:2.85%
cases:11.32%
controls:10.16%
cases:13.33%
controls:14.68%
18
173
147
1472
20
162
146
1490
7
51
159
1601
—
9
47
155
1605
18
166
141
1468
20
227
130
1319
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.2e+00
—
—
—
—
-1.0e+50
—
cases:3.03%
controls:0.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
5
16
160
1629
—
—
—
—
0
8
159
1626
—
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.39%
—
—
—
—
—
0
6
159
1628
0
6
150
1540
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
165
1629
—
—
—
—
—
—
finasteride; oral
D11AX10 [21602350]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Elastase.pancreatic [Mass/mass] in Stool
25907-7 [3000570]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
-1.4e-01
—
—
—
-1.0e+50
4.9e-01
4.4e-01
cases:4.24%
controls:4.86%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:3.14%
controls:1.96%
cases:9.33%
controls:6.21%
7
80
158
1565
—
—
—
0
6
164
1646
5
32
154
1602
14
96
136
1450
Kolposcopy
ULA02 [2001306679]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.36%
—
0
6
166
1646
—
—
—
0
6
159
1628
0
21
150
1525
No procedures
SPAT1301 [2001700402]
5.4e-01
5.9e-01
-1.0e+50
—
-1.0e+50
7.4e-01
-9.3e-02
cases:6.67%
controls:4.01%
cases:3.01%
controls:1.69%
cases:0.00%
controls:0.42%
—
—
cases:0.00%
controls:0.79%
cases:3.77%
controls:1.84%
cases:5.33%
controls:5.82%
11
66
154
1579
5
28
161
1624
0
7
166
1645
—
0
13
164
1639
6
30
153
1604
8
90
142
1456
Non-insulin dependent diabetes diabetic hypoglycaemic coma
E11.00 [2000501437]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Audiology
64 [38004489]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.33%
controls:2.72%
—
—
—
—
—
—
8
42
142
1504
metronidazole; oral, rectal
P01AB01 [21604857]
1.3e-01
—
—
—
—
1.0e+00
4.6e-01
cases:6.06%
controls:5.35%
—
—
—
—
—
—
—
—
cases:5.03%
controls:1.84%
cases:10.00%
controls:6.53%
10
88
155
1557
—
—
—
—
8
30
151
1604
15
101
135
1445
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.67%
—
—
—
—
—
—
—
5
11
154
1623
—
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
13
165
1632
—
—
—
—
—
0
5
150
1541
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5.2e-01
—
—
—
—
1.5e+00
5.4e-01
cases:4.24%
controls:2.55%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.73%
cases:5.33%
controls:3.17%
7
42
158
1603
—
—
—
—
5
12
154
1622
8
49
142
1497
Dietary counselling and surveillance
Z71.3 [45552101]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.52%
—
—
—
—
—
—
5
8
145
1538
pH of Venous blood
2746-6 [3012544]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1646
—
—
—
—
—
loperamide oxide; oral
A07DA05 [21600648]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.97%
—
—
—
—
—
—
6
15
144
1531
dalteparin; parenteral
B01AB04 [21600975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
promethazine, combinations
R06AD52 [21603489]
-3.1e-03
-1.0e+50
—
—
—
—
—
cases:3.03%
controls:3.04%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
5
50
160
1595
0
5
166
1647
—
—
—
—
—
C reactive protein [Mass/volume] in Blood by High sensitivity method
71426-1 [42870365]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
alfuzosin; oral
G04CA01 [21602668]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
5
165
1640
—
—
—
—
—
0
9
150
1537
C peptide [Moles/volume] in Serum or Plasma --fasting
42180-0 [3032836]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
150
1538
levodopa and decarboxylase inhibitor; oral
N04BA02 [21604465]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
6
159
1628
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
-3.1e-03
-1.0e+50
—
—
—
—
—
cases:3.03%
controls:3.04%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
5
50
160
1595
0
5
166
1647
—
—
—
—
—
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1646
—
—
—
—
—
olmesartan medoxomil; oral
C09CA08 [21601831]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
2.2e-01
—
—
—
—
—
-8.2e-02
cases:6.06%
controls:4.92%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:5.05%
10
81
155
1564
—
—
—
—
—
7
78
143
1468
Ankle symptom/complaint
L16 [2002000640]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.33%
controls:1.49%
—
—
—
—
—
—
5
23
145
1523
glimepiride; oral
A10BB12 [21600761]
—
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.78%
—
—
0
5
166
1647
—
—
0
10
159
1624
0
12
150
1534
Preventive immunization/medic
-44 [2002000115]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
8
159
1626
—
clindamycin; oral, parenteral
J01FF01 [21602985]
1.1e-01
—
—
—
—
—
6.3e-01
cases:3.64%
controls:3.28%
—
—
—
—
—
—
—
—
—
—
cases:6.00%
controls:3.30%
6
54
159
1591
—
—
—
—
—
9
51
141
1495
Glucose [Moles/volume] in Serum or Plasma --2 hours post dose glucose
14759-5 [3016701]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
11
150
1535
roxithromycin; oral
J01FA06 [21602974]
2.3e-01
—
—
—
—
—
7.7e-02
cases:6.67%
controls:5.35%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:4.33%
11
88
154
1557
—
—
—
—
—
7
67
143
1479
Mugwort IgE Ab [Units/volume] in Serum
6183-8 [3008401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
After-cataract
H26.4 [45600893]
1.5e+00
—
—
—
—
—
—
cases:3.03%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
5
11
160
1634
—
—
—
—
—
—
Hypothyroidism/myxoedema
T86 [2002001128]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.78%
—
—
—
—
—
—
6
12
144
1534
Lesion of ulnar nerve
G56.2 [45595951]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
7.2e-01
2.8e-01
—
—
-1.0e+50
7.5e-01
4.4e-01
cases:8.48%
controls:4.32%
cases:3.01%
controls:2.30%
—
—
—
—
cases:0.00%
controls:0.30%
cases:5.03%
controls:2.45%
cases:10.67%
controls:7.12%
14
71
151
1574
5
38
161
1614
—
—
0
5
164
1647
8
40
151
1594
16
110
134
1436
betaxolol; oral
C07AB05 [21601687]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
7
165
1638
0
5
166
1647
—
—
—
—
—
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
14
150
1532
Albumin [Mass/volume] in Urine
1754-1 [3012516]
-1.0e+50
-1.0e+50
—
—
—
—
-2.0e-01
cases:0.00%
controls:2.67%
cases:0.00%
controls:2.24%
—
—
—
—
—
—
—
—
cases:6.00%
controls:7.24%
0
44
165
1601
0
37
166
1615
—
—
—
—
9
112
141
1434
Presence of intraocular lens
Z96.1 [45585885]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
8
166
1644
—
—
—
0
6
159
1628
—
Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma
93769-8 [1002102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Eye pain
F01 [2002000399]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
Benign neoplasm: Colon, unspecified
D12.6 [45576377]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
165
1635
—
—
—
—
—
—
Supervision of other normal pregnancy
Z34.8 [45537628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
165
1622
—
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
1.0e-01
4.3e-01
—
—
—
6.0e-01
5.3e-01
cases:12.73%
controls:11.61%
cases:7.23%
controls:4.84%
—
—
—
—
—
—
cases:8.81%
controls:5.02%
cases:24.67%
controls:16.11%
21
191
144
1454
12
80
154
1572
—
—
—
14
82
145
1552
37
249
113
1297
carvedilol; oral
C07AG02 [21601700]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
5
166
1647
—
—
—
—
Angiography of the heart and coronary arteries
81 [2002100125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Acute sinusitis
J01 [45548098]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1647
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
1.3e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.86%
cases:8.00%
controls:2.59%
—
—
—
—
—
5
14
154
1620
12
40
138
1506
Preterm labour and delivery
O60 [45539187]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
7
165
1638
—
—
—
—
—
0
8
150
1538
piroxicam; ointment
M02AA07 [21604043]
3.5e-01
—
—
—
—
—
—
cases:4.24%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
—
—
7
50
158
1595
—
—
—
—
—
—
Flank/axilla symptom/complaint
L05 [2002000630]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
165
1636
—
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
3.6e-01
-2.1e-01
—
—
—
4.0e-01
6.5e-01
cases:18.79%
controls:13.92%
cases:3.61%
controls:4.42%
—
—
—
—
—
—
cases:5.66%
controls:3.86%
cases:22.00%
controls:12.81%
31
229
134
1416
6
73
160
1579
—
—
—
9
63
150
1571
33
198
117
1348
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.71%
—
0
6
166
1646
—
—
—
—
5
11
145
1535
Benign neoplasm: Rectum
D12.8 [45595734]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
2.4e-01
2.6e-01
-1.0e+50
—
—
-2.9e-01
-6.8e-03
cases:14.55%
controls:11.85%
cases:10.84%
controls:8.54%
cases:0.00%
controls:0.61%
—
—
—
—
cases:7.55%
controls:9.85%
cases:26.00%
controls:26.13%
24
195
141
1450
18
141
148
1511
0
10
166
1642
—
—
12
161
147
1473
39
404
111
1142
hydrocortisone; local oral
A01AC03 [21600036]
1.5e+00
—
—
—
—
—
1.4e+00
cases:3.03%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.97%
5
11
160
1634
—
—
—
—
—
6
15
144
1531
Vaccination
SPAT1325 [2001700426]
—
—
—
—
—
7.4e-01
-4.5e-02
—
—
—
—
—
—
—
—
—
—
cases:4.40%
controls:2.14%
cases:5.33%
controls:5.56%
—
—
—
—
—
7
35
152
1599
8
86
142
1460
valsartan and amlodipine
C09DB01 [21601842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
165
1639
—
—
—
—
—
—
Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
49891-5 [3029511]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
7
165
1638
—
—
—
—
—
0
11
150
1535
Suture or reinsertation of rotator cuff of shoulder
NBL00 [2001307341]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:4.26%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
0
70
165
1575
0
12
166
1640
—
—
—
—
—
Alzheimer disease with late onset
G30.1 [45552521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.68%
—
—
—
—
—
—
0
26
150
1520
Other specified counselling
Z71.8 [45581061]
8.2e-01
—
—
—
—
1.3e+00
7.2e-02
cases:4.85%
controls:2.19%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.86%
cases:5.33%
controls:4.98%
8
36
157
1609
—
—
—
—
5
14
154
1620
8
77
142
1469
lactulose; oral
A06AD11 [21600571]
1.1e+00
—
—
—
—
1.6e+00
9.5e-01
cases:5.45%
controls:1.95%
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.92%
cases:5.33%
controls:2.13%
9
32
156
1613
—
—
—
—
7
15
152
1619
8
33
142
1513
Pain localized to upper abdomen
R10.1 [45568111]
—
—
—
—
—
-1.0e+50
6.6e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:3.33%
controls:1.75%
—
—
—
—
—
0
6
159
1628
5
27
145
1519
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.1e+00
—
—
—
—
—
1.3e+00
cases:3.03%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:1.36%
5
17
160
1628
—
—
—
—
—
7
21
143
1525
Rhinopharyngoscopy
UDH02 [2001301680]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
165
1637
—
—
—
—
—
—
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
150
1537
Other ultrasound examination during pregnancy
SPAT1189 [2001700290]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
telmisartan; oral
C09CA07 [21601830]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
6
166
1646
—
—
—
—
Mouth breathing
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
165
1636
—
—
—
—
—
—
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
14
150
1532
topiramate; oral
N03AX11 [21604433]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
0
5
159
1629
—
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
150
1539
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
1.6e+00
—
—
—
—
2.2e+00
1.6e+00
cases:3.64%
controls:0.73%
—
—
—
—
—
—
—
—
cases:3.14%
controls:0.37%
cases:4.67%
controls:0.97%
6
12
159
1633
—
—
—
—
5
6
154
1628
7
15
143
1531
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
150
1541
Laparoscopic appendectomy
JEA01 [2001304803]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
165
1638
—
—
—
—
—
—
ticagrelor; oral
B01AC24 [40252640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
150
1540
Vacuum extractor delivery
O81.4 [45582577]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
150
1537
Papillary carcinoma of the thyroid gland (thyroid gland)
C73.91 [2000501197]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
—
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
10
165
1635
—
—
—
—
0
7
159
1627
—
Abdominal ultrasound examination
JN3AE [2001305555]
1.5e+00
—
—
—
—
-1.0e+50
1.4e+00
cases:3.03%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:4.00%
controls:1.03%
5
11
160
1634
—
—
—
—
0
6
159
1628
6
16
144
1530
allopurinol; oral, parenteral
M04AA01 [21604131]
1.1e+00
1.5e+00
—
—
—
—
—
cases:3.03%
controls:1.03%
cases:3.01%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
5
17
160
1628
5
11
161
1641
—
—
—
—
—
Blood transfusion
WW500 [2001310603]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
5
165
1640
0
5
166
1647
—
—
—
—
—
hyaluronic acid; parenteral
M09AX01 [21604179]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
5
165
1640
—
—
—
—
—
0
8
150
1538
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
8.8e-01
—
—
—
1.2e+00
3.3e-01
—
—
cases:3.01%
controls:1.27%
—
—
—
—
—
—
cases:3.77%
controls:1.22%
cases:6.00%
controls:4.40%
—
5
21
161
1631
—
—
—
6
20
153
1614
9
68
141
1478
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
—
—
—
—
—
—
3.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:3.36%
—
—
—
—
—
—
7
52
143
1494

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
185
1413
7.66
14.20
14.5
4.8
16.51
14.60
pmol/l
15.45
176
1300
186
1614
4.69
6.63
16.3
5.7
2.08
1.85
mu/l
0.93
177
1503
98
661
1.98
5.13
17.9
11.3
1.21
1.17
inr
0.33
90
541
86
555
1.99
5.11
1.4
1.6
0.53
2.09
u/ml
2.16
23
136
90
627
1.81
3.98
5.7
6.5
—
—
—
0
0
72
479
1.80
3.64
1.9
2.2
156.96
166.10
u/l
0.06
67
460
17
64
2.82
3.50
2.1
2.1
1.80
5.89
iu/l
—
9
26
41
233
1.96
3.35
2.1
1.6
1380.01
1243.13
nmol/l
0.38
33
170
78
546
1.72
3.23
5.1
4.0
34.72
31.55
ng/l
0.09
47
351
109
837
1.69
3.19
10.6
7.3
1.21
1.22
mmol/l
0.87
93
720
11
30
3.82
3.14
1.1
1.1
—
—
—
0
0
72
498
1.71
3.09
2.4
2.7
2.81
2.67
mg/l
0.24
66
426
123
983
1.69
3.03
3.8
3.3
71.33
74.05
ug/l
0.10
117
924
12
41
3.05
2.67
2.9
3.9
92.08
90.76
%
0.31
12
41
45
286
1.75
2.56
6.0
3.5
23.12
516.34
ng/l
2.62
33
185
58
396
1.66
2.55
4.9
3.9
—
—
—
0
0
109
868
1.58
2.53
6.5
6.8
8.56
8.41
%
0.24
103
819
15
63
2.50
2.53
5.7
3.8
23.96
23.68
mmol/l
0.11
15
63
30
169
1.92
2.50
2.1
2.0
0.00
0.00
estimate
—
5
44
11
38
3.01
2.46
1.9
2.1
—
—
—
0
0
108
863
1.57
2.44
6.3
6.7
54.50
56.63
%
1.11
103
829
8
22
3.75
2.39
1.1
1.0
—
—
—
0
0
116
945
1.57
2.38
5.9
6.8
0.59
0.54
e9/l
1.16
101
815
108
866
1.56
2.38
6.5
6.8
0.63
0.67
%
0.28
102
814
108
866
1.56
2.38
6.4
6.8
2.97
2.86
%
0.17
101
817
25
135
1.98
2.35
10.4
4.9
7.42
7.35
ph
1.12
20
92
92
714
1.55
2.33
2.1
1.9
97.75
95.94
pmol/l
0.12
48
353
110
891
1.54
2.28
6.2
6.7
30.07
29.37
%
0.27
104
852
42
272
1.69
2.23
1.3
1.5
500.00
555.56
titre
0.12
12
63
96
759
1.52
2.20
9.4
7.4
1.21
1.22
mmol/l
0.61
91
704
115
947
1.53
2.16
5.9
6.8
0.04
0.04
e9/l
0.03
100
812
26
147
1.89
2.15
4.8
5.7
5.06
5.04
kpa
0.06
26
141
14
63
2.32
2.06
3.4
3.6
—
—
—
0
0
142
1232
1.57
2.04
10.2
7.9
92.72
80.92
u/l
0.57
135
1159
116
965
1.50
2.02
5.9
6.8
1.94
1.92
e9/l
0.12
100
857
117
979
1.49
1.96
6.2
7.0
0.21
0.19
e9/l
0.63
103
856
22
125
1.86
1.81
1.2
1.2
—
16.00
—
0
5
11
48
2.37
1.74
1.2
2.0
3.82
3.66
mmol/l
0.16
11
43
56
412
1.50
1.74
3.6
4.2
1.02
1.02
kg/l
0.12
40
255
28
175
1.70
1.69
1.4
1.3
243.09
133.06
u/ml
0.43
11
68
159
1439
1.58
1.66
7.8
5.7
39.58
38.23
mmol/mol
0.78
146
1348
16
85
1.96
1.60
2.1
2.0
0.00
0.00
estimate
—
5
33
75
594
1.43
1.58
3.5
3.0
—
—
—
0
0
65
505
1.43
1.51
3.8
4.5
0.00
0.01
estimate
0.50
20
192
64
496
1.43
1.51
5.1
3.9
7.40
7.40
ph
0.16
53
344
63
489
1.43
1.47
1.6
1.6
19.91
22.69
nmol/l
0.88
56
406
10
47
2.19
1.36
1.6
2.0
133.90
126.75
g/l
—
10
36
110
948
1.37
1.35
3.7
4.3
58.70
7.92
estimate
0.40
20
205
32
220
1.54
1.35
3.9
3.0
3.87
6.59
e9/l
0.88
27
195
21
130
1.69
1.33
4.5
3.1
0.27
0.80
e6/l
0.36
21
125
111
960
1.37
1.32
3.8
4.4
0.00
0.00
estimate
-0.00
20
194
10
48
2.14
1.30
3.1
2.4
7.41
7.42
ph
—
10
48
15
85
1.83
1.27
1.4
2.4
—
—
—
0
0
63
501
1.38
1.26
1.5
1.5
2.05
2.03
g/l
0.03
31
292
92
777
1.35
1.26
3.0
3.7
6.30
6.25
ph
0.13
45
395
8
36
2.27
1.26
2.5
2.6
9.08
9.01
kpa
—
8
36
8
36
2.27
1.26
2.5
2.6
5.66
5.09
kpa
—
8
36
109
946
1.35
1.24
3.7
4.2
0.00
0.00
estimate
-0.00
18
201
14
79
1.83
1.20
1.2
1.3
—
—
—
0
0
23
151
1.59
1.18
10.0
8.4
5.50
5.18
kpa
0.95
23
144
23
151
1.59
1.18
10.0
8.4
9.82
13.01
kpa
4.99
23
145
51
396
1.39
1.17
1.7
2.1
0.62
0.94
mg/l
1.38
39
296
0
35
0.00
1.16
0.0
2.9
—
7.16
—
0
35
31
221
1.48
1.12
2.1
2.0
—
—
—
0
0
23
330
0.66
1.09
1.6
1.7
—
—
—
0
0
9
46
2.00
1.05
1.2
2.1
3.11
17.91
e6/l
—
9
33
20
131
1.59
1.05
5.3
3.6
1.22
1.23
mmol/l
0.20
20
112
5
22
2.31
1.04
1.0
1.0
—
—
—
0
0
9
47
1.96
1.03
1.2
2.1
336.44
322.75
e6/l
—
9
36
5
23
2.20
0.98
1.0
1.8
—
—
—
0
0
28
201
1.46
0.98
2.6
1.6
—
—
—
0
0
7
36
1.98
0.98
3.9
2.2
9.74
5.85
pmol/l
—
7
36
7
36
1.98
0.98
1.3
2.4
—
—
—
0
0
130
1182
1.30
0.94
6.3
5.1
18.33
132.82
e6/l
—
6
17
63
522
1.31
0.94
5.7
3.3
6.27
7.97
mmol/l
2.81
54
442
22
152
1.50
0.93
3.5
2.6
6.50
6.18
ph
1.07
16
97
52
420
1.33
0.92
5.0
3.3
48.74
39.92
mg/l
0.09
32
264
5
102
0.48
0.92
1.4
1.6
—
—
—
0
0
11
63
1.79
0.92
2.5
5.1
36.86
36.94
°c
0.22
11
63
18
119
1.57
0.92
1.2
2.6
67.26
66.31
g/l
0.27
18
110
53
432
1.31
0.88
5.7
3.8
10.82
6.81
mg/mmol
0.23
35
263
117
1055
1.27
0.88
8.3
9.8
3.76
3.96
e9/l
0.56
103
920
50
607
0.76
0.88
1.5
1.7
—
—
—
0
0
6
30
2.03
0.87
1.3
1.6
16.65
19.05
ng/l
—
6
30
11
65
1.73
0.84
1.6
1.9
1.13
1.45
g/l
0.65
11
58
80
694
1.26
0.82
3.5
4.1
0.00
0.02
estimate
0.50
15
167
5
99
0.49
0.80
1.4
1.5
—
—
—
0
0
19
132
1.49
0.79
1.3
1.2
—
—
—
0
0
46
374
1.30
0.78
3.6
3.4
319.17
320.20
umol/l
0.02
40
337
5
25
2.03
0.73
1.6
1.4
—
—
—
0
0
112
1019
1.23
0.72
6.9
5.2
6.73
6.38
mmol/l
0.82
106
933
20
144
1.43
0.71
3.7
3.9
4.28
56.54
ug/l
0.54
13
115
21
153
1.42
0.70
1.5
1.2
131.83
417.31
u/ml
0.88
21
139
12
77
1.60
0.70
1.8
1.8
—
—
—
0
0
69
598
1.24
0.70
2.7
3.0
2.34
2.37
mmol/l
1.14
63
539
79
695
1.23
0.69
2.1
2.0
—
—
—
0
0
7
42
1.69
0.69
1.0
1.2
—
—
—
0
0
27
207
1.35
0.68
1.4
1.2
—
—
—
0
0
162
1542
1.31
0.67
5.8
4.5
5.91
5.72
mmol/l
0.79
151
1414
153
1448
1.27
0.65
4.7
3.9
1.23
1.20
mmol/l
0.29
142
1321
24
184
1.35
0.61
1.3
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
3.1
—
106.25
—
0
20
0
20
0.00
0.60
0.0
3.1
—
1.19
—
0
20
0
20
0.00
0.60
0.0
3.2
—
3.90
—
0
20
20
150
1.37
0.58
10.6
8.5
7.41
7.42
ph
0.14
11
76
8
125
0.62
0.56
1.8
3.1
11.41
42.42
u/ml
—
8
119
9
59
1.55
0.56
1.1
1.4
—
56.67
—
0
6
6
38
1.60
0.55
1.3
2.4
16.60
15.87
%
—
6
38
163
1564
1.26
0.53
6.1
5.2
2.62
2.72
mmol/l
0.80
149
1452
6
39
1.56
0.53
1.0
1.1
—
—
—
0
0
6
39
1.56
0.53
1.0
1.1
—
—
—
0
0
64
566
1.20
0.52
6.3
6.4
—
—
—
0
0
161
1548
1.24
0.48
5.6
4.7
4.53
4.65
mmol/l
0.90
150
1439
160
1539
1.23
0.46
5.5
4.6
1.45
1.53
mmol/l
1.50
147
1422
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
42
365
1.19
0.41
1.5
1.3
15.47
32.23
iu/ml
1.51
15
104
60
538
1.17
0.41
3.3
3.5
0.00
0.01
estimate
0.50
13
163
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
18
224
0.78
0.39
5.2
5.7
7.34
7.38
ph
—
6
143
18
146
1.26
0.33
9.1
5.1
118.94
69.58
ng/l
0.96
18
133
32
277
1.19
0.33
1.7
1.6
—
—
—
0
0
14
110
1.29
0.32
5.6
6.5
—
—
—
0
0
175
1712
1.23
0.31
21.4
14.4
18.36
21.35
mg/l
0.79
144
1352
18
148
1.24
0.30
2.7
2.4
298.40
5616.25
u/l
—
5
55
17
139
1.24
0.30
3.7
3.0
71.71
73.68
e9/l
—
10
99
8
106
0.74
0.30
1.0
1.1
—
—
—
0
0
18
214
0.82
0.28
1.2
1.2
—
—
—
0
0
21
178
1.20
0.27
2.0
2.6
35.79
27.94
u/l
0.50
14
149
33
292
1.16
0.27
1.7
3.1
82.58
94.38
ug/g
0.15
24
226
179
1759
1.23
0.26
19.9
12.2
—
—
—
0
0
18
151
1.21
0.26
3.4
3.9
—
—
—
0
0
90
852
1.11
0.25
12.7
11.1
0.00
0.00
e9/l
0.50
72
685
179
1760
1.22
0.25
25.9
17.2
75.25
68.59
umol/l
0.73
174
1725
12
96
1.27
0.25
1.8
1.9
—
—
—
0
0
18
211
0.84
0.24
5.1
5.9
0.94
1.60
mmol/l
0.34
18
175
146
1499
0.89
0.23
24.0
18.0
13.48
13.44
%
0.15
146
1488
16
135
1.20
0.22
1.5
1.4
—
—
—
0
0
15
126
1.21
0.21
1.7
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
114.85
—
0
11
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
48
446
1.10
0.19
4.1
4.9
—
—
—
0
0
7
62
1.13
0.17
1.1
1.2
—
—
—
0
0
32
349
0.90
0.17
1.8
1.9
—
—
—
0
0
62
592
1.07
0.13
4.5
3.7
25.42
42.28
e6/l
0.64
50
444
86
831
1.06
0.13
2.9
2.8
—
—
estimate
—
0
0
33
353
0.92
0.12
1.5
1.3
1.11
10.04
u/ml
2.61
11
132
46
437
1.07
0.11
2.0
1.8
—
—
—
0
0
14
156
0.89
0.10
1.4
1.5
—
—
—
0
0
5
48
1.04
0.09
25.4
8.1
—
—
—
0
0
23
214
1.08
0.09
1.9
1.5
—
—
—
0
0
7
68
1.03
0.08
7.7
1.7
—
—
—
0
0
67
652
1.04
0.07
2.9
3.0
—
—
—
0
0
9
88
1.02
0.07
1.3
5.2
0.53
0.64
%
—
9
88
60
583
1.04
0.06
2.5
2.3
—
—
—
0
0
31
296
1.06
0.06
2.7
3.3
4.31
3.05
e6/l
0.43
15
144
16
149
1.08
0.05
5.3
5.9
0.00
0.05
%
—
5
38
19
179
1.07
0.05
1.5
1.5
—
—
—
0
0
15
140
1.08
0.04
1.6
1.8
1.77
1.56
g/l
0.14
15
129
12
111
1.09
0.04
1.3
1.3
—
—
—
0
0
22
210
1.05
0.04
2.0
4.1
6.09
5.83
umol/l
0.09
22
181
18
189
0.95
0.03
12.3
9.7
—
—
—
0
0
11
118
0.93
0.03
5.3
1.6
—
—
—
0
0
15
142
1.06
0.02
2.8
5.4
0.60
0.50
%
—
5
40
13
123
1.06
0.01
4.7
1.6
—
—
—
0
0
51
518
0.98
0.01
3.6
3.5
0.16
0.35
e6/l
0.82
37
372
68
688
0.98
0.01
2.3
1.9
1.17
1.29
mmol/l
0.78
62
582
56
554
1.02
0.00
2.7
3.2
—
0.00
—
0
8
13
126
1.03
0.00
1.8
1.5
—
—
—
0
0
24
236
1.02
0.00
1.0
1.3
—
—
—
0
0
15
149
1.01
0.00
13.7
8.2
10.03
7.68
mmol/l
0.56
15
141
70
701
1.00
0.00
4.9
4.6
73.34
67.95
e6/l
0.05
51
465
12
123
0.97
0.00
4.9
1.6
—
—
—
0
0
16
163
0.98
0.00
9.2
9.5
25.78
25.28
mmol/l
0.21
16
163
22
215
1.03
0.00
9.8
6.7
103.95
104.41
mmol/l
0.17
22
215
51
508
1.01
0.00
2.4
2.2
—
—
—
0
0
13
125
1.04
0.00
4.7
1.6
—
—
—
0
0
11
108
1.02
0.00
1.3
1.6
—
—
—
0
0
6
64
0.94
0.00
1.5
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
8
79
1.01
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
186
1857
1.04
-0.00
32.3
21.8
4.45
4.44
e12/l
0.15
181
1814
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
0.00
—
0
7
7
70
1.00
-0.00
1.1
1.8
—
12.28
—
0
5
5
52
0.96
-0.00
1.2
1.1
—
19.37
—
0
13
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
8
82
0.97
-0.00
1.1
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
9.9
—
8.90
—
0
8
9
89
1.01
-0.00
1.3
5.2
1.59
1.25
%
—
9
89
0
5
0.00
-0.00
0.0
1.6
—
60.60
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
26.75
—
0
8
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
68
0.88
-0.00
1.2
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.8
—
5.78
—
0
5
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: E4_CONGENITAL_HYPOTHYROIDISM_WITHOUT_GOITER – Congenital hypothyroidism without goiter

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).